Werewolf Therapeutics, Inc.

Werewolf Therapeutics, Inc.

Biotechnology • Healthcare • Watertown, MA, United States • HOWL (NMS)

Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; WTX-921, a conditionally activated IL-10 INDUKINE molecule for the treatment of inflammatory bowel disease and potentially other inflammatory diseases; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.

Stock Performance (90 Days)

Data through Dec 24, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Werewolf Therapeutics (HOWL) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Yahoo Finance • Dec 15
Werewolf Therapeutics Announces Pipeline and Business Updates - Investing News Network
Investing News Network • Dec 18
HC Wainwright & Co. Maintains Werewolf Therapeutics (HOWL) Buy Recommendation - Nasdaq
Nasdaq • Dec 19
Werewolf Therapeutics (HOWL) 10% owners sell $241k in stock - Investing.com
Investing.com • Nov 12
Luke Evnin Sells 37,104 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock - MarketBeat
MarketBeat • Dec 13

Other Biotechnology Companies

View All →
CODEXIS, INC. logo Codexis, Inc.
1 layoff tracked
$144.5M market cap
VERTEX PHARMACEUTICALS INC / MA logo Vertex Pharmaceuticals Inc. / MA
$118.68B market cap
REGENERON PHARMACEUTICALS, INC. logo Regeneron Pharmaceuticals, Inc.
$82.72B market cap
ALNYLAM PHARMACEUTICALS, INC. logo Alnylam Pharmaceuticals, Inc.
$52.92B market cap
ARGENX SE logo Argenx SE
$52.62B market cap
INSMED Inc logo Insmed Inc.
$37.61B market cap

Frequently Asked Questions

Has Werewolf Therapeutics, Inc. had layoffs?
No layoff events have been recorded for Werewolf Therapeutics, Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does Werewolf Therapeutics, Inc. have?
Werewolf Therapeutics, Inc. has approximately 39 employees.
What industry is Werewolf Therapeutics, Inc. in?
Werewolf Therapeutics, Inc. operates in the Biotechnology industry, within the Healthcare sector.
Is Werewolf Therapeutics, Inc. a publicly traded company?
Yes, Werewolf Therapeutics, Inc. is publicly traded under the ticker symbol HOWL on the NMS. The company has a market capitalization of approximately $0.03 billion.
Where is Werewolf Therapeutics, Inc. headquartered?
Werewolf Therapeutics, Inc. is headquartered in Watertown, MA, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.